Participated · Series C · Jul 2023

Frontier Field develops and provides 日病モバイル, a secure smartphone service for hospitals that supports staff calls and communications. The service includes integration with nurse call systems and electronic medical records to streamline workflows. Launched in 2020 to accelerate DX for physicians and nurses, the product aims to replace shrinking PHS usage and address upcoming 2024 working-hours reforms. 日病モバイル is positioned as a hub to connect medical systems, devices, and personnel rather than merely a PHS replacement. The service is currently used by about 60 hospitals and more than 20,000 healthcare workers. The company recently completed a Series C that includes debt financing and will use the proceeds to improve the convenience and value of 日病モバイル. フロンティア・フィールド operates “日病モバイル”, a secure smartphone and DX service built for hospitals that connects carrier switches to the company’s system via IP‑VPN and dedicated lines to protect patient data. The platform offers hospital-specific integrations and apps — including nurse‑call and electronic medical record linkage, emergency alerting, and multi‑vendor SIP/VoIP support — to simplify multi‑professional coordination while reducing personal data leakage risk. It is designed to replace PHS, paper, and fax workflows and to enable direct data entry in home‑visit care, eliminating double data entry. The company has deployed 日病モバイル in 19 hospitals as of March 2022 and, with Japan Hospital Association cooperation, targets about 40 hospitals by December 2022 and 300 hospitals / 60,000 lines by the end of 2024. The service emphasizes a closed network model to address hospitals’ sensitivity about Internet connectivity and offers a common authentication basis for multiple applications. The company was founded in July 2016 by Yasuyuki Sato, a former NTT Docomo and Japan Altmark executive.

Participated · Series C · Aug 2022

Ubie, founded in 2017 and based in New York, offers the Ubie AI Symptom Checker, a medically vetted platform that guides users to appropriate care pathways using predictive models. The company supports over 1,800 provider organizations and leverages disease-prediction AI to help patients navigate healthcare systems. As of June 2025 Ubie has secured over $125 million in cumulative funding. The reported capital will be used to support U.S. expansion, develop generative AI for patient education, and continue refining provider-focused solutions in partnership with the Mayo Clinic. Investors named in the report include Google, JAPAN POST CAPITAL, NTT DOCOMO, SEVEN-ELEVEN JAPAN, Japan Finance Corporation and The Shoko Chukin Bank. Ubie is a healthtech company founded in May 2017 that builds AI-powered products to guide people to appropriate medical care. Its consumer offerings include the symptom search engine Ubie (Japanese and US versions) and Ubie Disease Q&A, together reaching about 10 million monthly users. For healthcare providers it offers Ubie AI Medical Navi, a digital intake and diagnosis-support tool adopted by more than 1,700 medical institutions since its 2018 launch. The company also operates matching businesses that connect consumers and medical providers and has collaborated with pharmaceutical firms, engaging with over two-thirds of global mega‑pharma since its pharma business launch in late 2021. Ubie established a U.S. office in 2022 as part of its international expansion. It plans to use recent funding to grow its pharma-facing business, enhance consumer service features, develop new businesses, and invest in system development and marketing for the Ubie platform. Ubie provides an AI-powered symptom checker app for consumers and a B2B hospital product called Ubie for Hospital (AI Monshin) that automates preliminary patient interviews. AI Monshin selects and asks around 20 questions from 3,500 question types using data extracted from about 50,000 medical research papers. More than 1,100 medical institutions in Japan use AI Monshin, and the consumer app has over 7 million monthly active users. The company employs approximately 200 people. Ubie launched its symptom checker in the U.S. earlier this year, opened a U.S. subsidiary in October, and entered Singapore in August as initial steps toward global expansion. It plans to scale its healthcare platform and ramp up U.S. penetration, while pursuing partnerships with pharmaceutical companies (many based on the U.S. East Coast). Ubie offers an AI-powered patient questionnaire that guides patients from symptoms to appropriate medical care and improves operational efficiency in the medical field. The company is led by CEO Yoshinori Abe. It is building a medical data platform to connect patients, medical institutions, and pharmaceutical companies. Ubie says the platform will help ensure patients visit the right medical institution at the right time and help physicians access relevant, up-to-date knowledge. The company also aims to help pharmaceutical companies provide patients with appropriate information and scientific findings related to their conditions. Ubie intends to use its recent funding to support business growth in Japan and the U.S.